Finance

Beta
Lists
Z1TS34:BVMF
Zoetis Inc Bdr
23,90 R$
+1,79%
(+0,42) 1D
15 шіл., 10:38:42 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for Z1TS34...
Open
23,75 R$
High
23,90 R$
Low
23,75 R$
Mkt. cap
31,64 млрд
Avg. vol.
4,03 мың
Volume
1,10 мың
52-wk high
55,31 R$
52-wk low
23,00 R$
Shares outstanding
419,23 млн
No. of employees
14 мың
Open
23,75 R$
High
23,90 R$
Low
23,75 R$
Mkt. cap
31,64 млрд
Avg. vol.
4,03 мың
Volume
1,10 мың
52-wk high
55,31 R$
52-wk low
23,00 R$
Shares outstanding
419,23 млн
No. of employees
14 мың
News stories
From sources across the web
Yahoo Finance Singapore
Yahoo Finance Singapore
·
15 сағат бұрын
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
Investing.com Canada
Investing.com Canada
·
16 сағат бұрын
Form 4 Zoetis Inc For: 14 July By Investing.com
Profile
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. Wikipedia
About Zoetis Inc Bdr
CEOKristin C. Peck
Employees14,5 мың
Founded1952
HeadquartersParsippany-Troy Hills, Нью-Джерси, Америка Құрама Штаттары
SectorPharmaceutical industry
Websitezoetis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 ж. мау.
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
Revenue
2,46 млрд
2,40 млрд
2,39 млрд
2,26 млрд
Cost of goods sold
647,00 млн
682,00 млн
711,00 млн
640,00 млн
Cost of revenue
647,00 млн
682,00 млн
711,00 млн
640,00 млн
Research and development expenses
172,00 млн
170,00 млн
199,00 млн
180,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
608,00 млн
572,00 млн
618,00 млн
584,00 млн
Operating expense
813,00 млн
774,00 млн
848,00 млн
795,00 млн
Total operating expenses
1,46 млрд
1,46 млрд
1,56 млрд
1,44 млрд
Operating income
1,00 млрд
944,00 млн
828,00 млн
827,00 млн
Other non operating income
-1,00 млн
-
-6,00 млн
-1,00 млн
EBT including unusual items
902,00 млн
887,00 млн
761,00 млн
758,00 млн
EBT excluding unusual items
951,00 млн
899,00 млн
780,00 млн
779,00 млн
Income tax expense
184,00 млн
166,00 млн
158,00 млн
157,00 млн
Effective tax rate
20,40%
18,71%
20,76%
20,71%
Other operating expenses
-
-
-
-
Net income
718,00 млн
721,00 млн
603,00 млн
601,00 млн
Net profit margin
29,19%
30,04%
25,26%
26,57%
Earnings per share
1,76
1,70
1,48
1,53
Interest and investment income
19,00 млн
26,00 млн
25,00 млн
21,00 млн
Interest expense
-53,00 млн
-58,00 млн
-57,00 млн
-62,00 млн
Net interest expenses
-34,00 млн
-32,00 млн
-32,00 млн
-41,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,12 млрд
1,07 млрд
903,00 млн
946,00 млн
Gain or loss from assets sale
3,00 млн
-
-
-6,00 млн
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more